The DOI matches its Crossref record.
Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“It inhibits the activity of gastric and pancreatic lipases and decreases dietary lipid digestion and absorption by 30% (212).”
BackgroundSjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Appropriate Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults
JAKICIC (CHAIR), J. M., CLARK, K., COLEMAN, E., DONNELLY, J. E., FOREYT, J., MELANSON, E., VOLEK, J., & VOLPE, S. L. (2001) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200112000-00026 · Cited by 752
Orlistat, a New Lipase Inhibitor for the Management of Obesity
Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.4.270.34882 · Cited by 572
Metadata
- Authors
- Hauptman, J., Jeunet, F., & Hartmann, D.
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 1992-01
- Volume
- 55
- Issue
- 1
- Pages
- 309S-313S
- ISSN
- 0002-9165 (ISSN-L)
- OpenAlex
- W2184401029
- Cited by
- 182
- References
- 0
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin). https://app.cochat.ai/papers/10.1093/ajcn/55.1.309s
- The paper
- Hauptman, J., Jeunet, F., & Hartmann, D. (1992). Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin). The American Journal of Clinical Nutrition. https://doi.org/10.1093/ajcn/55.1.309s
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.